Could hip cartilage repair be an option for me?

Cartilage repair tends to come into the conversation when hip pain is being driven by a specific area of cartilage damage in the hip joint, and the aim is to keep the native joint working for longer rather than moving straight to a hip replacement. That is a different goal from general pain management, where treatments may focus on short-term symptom control rather than changing the underlying joint surface.

Hip articular cartilage is the smooth, low-friction lining on the ball and socket surfaces that helps the hip joint glide under load. When the damage is focal (a defined defect or “pothole” in the cartilage), preservation techniques may be considered; when the wear is diffuse (more like “tread worn off” across much of the joint, as in established osteoarthritis), focal repair is less likely to work. In a 2017 review of hip chondral surgery, outcomes were emphasised as being better when joint space is preserved and radiographic arthritis is limited (often described as Tönnis grade <2), with focal repair generally considered ineffective once arthritis is more advanced.

A practical way of grouping hip joint options is a four-step pathway, moving from symptom control towards structural solutions:

• Symptom management: physiotherapy, activity modification, tablets, and (in some cases) image-guided injections for flare control.
• Biologic/scaffold support: image-guided injections intended to support the joint environment; at Lincolnshire Hip this may include an injectable collagen scaffold sometimes referred to as “liquid cartilage” (ChondroFiller), where evidence in the hip is still emerging.
• Cartilage restoration/repair surgery: procedures for focal lesions, such as AMIC (a membrane plus bone-marrow stimulation technique) and, for larger/deeper osteochondral injuries in selected younger adults, osteochondral allograft (OCA).
• Hip replacement: when the joint is too globally worn for preservation to be realistic.

This section keeps the emphasis on the decision factors (symptoms, MRI findings, and X-ray joint space) rather than booking logistics. Broadly, an MRI showing a localised defect alongside an X-ray that still shows preserved joint space tends to place people in the “hip preservation” bucket; widespread narrowing and established osteoarthritis tends to place people in the “replacement or symptom management” bucket.

Lincolnshire Hip provides a hip-only, consultant-led pathway (Professor Paul Lee) with local assessment in Grantham and Sleaford, focused on deciding between hip preservation options and hip replacement where appropriate. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

What is ChondroFiller liquid cartilage at Lincolnshire Hip?

ChondroFiller™ (often described as “liquid cartilage”) is described in the hip literature as an injectable, cell‑free collagen-based scaffold intended to sit in a focal cartilage defect and support repair tissue formation, rather than act as an immediate anti‑inflammatory.

At Lincolnshire Hip, ChondroFiller is positioned on the pathway as an outpatient, ultrasound‑guided hip joint injection: image guidance is used to place the material accurately within the joint space. Rather than focusing on the scan itself, the meaningful distinction is that this is intended as a structure‑supporting scaffold approach for selected hip joint problems, not a short‑term flare treatment.

In day‑to‑day terms, people usually judge whether it is helping by changes in pain during walking, stairs and daily activities, and whether hip movement feels freer over the following weeks. What remains uncertain is whether ChondroFiller changes the longer‑term course seen on X‑ray arthritis progression, or reliably prevents the future need for hip replacement in the way that no injection has yet been shown to do for established osteoarthritis.

Evidence in the hip joint is still relatively small. A 2025 case report described a 32‑year‑old with an isolated femoral head osteochondral defect treated arthroscopically with ChondroFiller (without microfracture), reporting complete pain relief with restored range of motion and gait at follow‑up, while noting the need for longer‑term studies. In a 2023 updated systematic review of arthroscopic hip joint preservation techniques, ChondroFiller gel appeared in single‑study data with survival reported at 92.3%, which is encouraging but not the same as having large, long‑term hip trials.

ChondroFiller also sits in a different category from standard pain‑relief injections: the intended goal is scaffold support for a focal defect, rather than short-term symptom suppression.

When is AMIC hip cartilage repair surgery considered?

AMIC (autologous matrix‑induced chondrogenesis) tends to enter the hip joint discussion when scans show a single, symptomatic patch of cartilage that is too substantial for “tidying up” alone but not yet part of established, widespread arthritis. In the hip, expert reviews commonly describe it for full‑thickness (3rd–4th degree) defects that are still focal and are roughly ≥2 cm², most often in younger or biologically “younger” patients where joint space is still preserved (often summarised as Tönnis <2 on X‑ray).

When might osteochondral allograft be used in the hip joint?

Osteochondral allograft (often shortened to OCA) is a hip joint–preserving operation used when the damaged area is not just “surface wear” but a deeper osteochondral injury—meaning cartilage and the supporting bone beneath it. In hip terms, it most often involves transplanting a shaped plug or segment from a donor to restore part of the femoral head joint surface, with the aim of recreating a smoother, more congruent ball-and-socket contact than the injured hip can achieve on its own.

OCA tends to be discussed for a relatively small group of patients—often people in their 20s or early 30s—where the defect is large, deep or post-injury, and simpler approaches are less likely to be enough.

Because of access, exposure and graft handling, published modern hip OCA series report performing femoral head OCA via surgical hip dislocation, which is an open specialist approach rather than routine first-line arthroscopy. In a 2025 series of 24 patients (mean age 22.4 years) with mean follow-up of 47.9 months, hip scores improved on average, yet 25% still converted to hip arthroplasty at a mean 3.8 years. Another 2025 report of 29 patients (mean age 21.6 years) found a 13.7% conversion rate at about 41.5 months.

At Lincolnshire Hip, these figures are used to support lifetime planning conversations: for someone facing an otherwise “too-young” hip replacement, a complex graft-based preservation procedure may be one way to defer arthroplasty for a period of years, while recognising that a hip replacement can still become necessary later. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

What does recovery after hip cartilage repair usually involve?

Recovery after hip cartilage repair is usually best understood as a set of phases rather than a single “better” day. To make this section more useful in practice, the milestones below describe typical phases rather than fixed timepoints, while recognising that the exact pace can change with defect size/location, pain levels and the operating team’s protocol.

ChondroFiller (ultrasound-guided hip joint injection)

In the first few days, a temporary pain flare or deep ache in the hip/groin can occur, alongside local tenderness from the injection itself. Activity is usually kept comfortable early on, with a gradual return towards usual day-to-day walking as symptoms allow.

Over the following weeks, rehabilitation commonly focuses on restoring smooth hip range of motion and rebuilding low-load strength (for example, gluteal control and hip stability) without provoking sharp joint pain. If improvement happens, it is more often described as building over time rather than an immediate effect, reflecting the still-emerging hip-specific evidence base for scaffold-type treatments (including single-study survival reporting in hip series).

AMIC (surgical cartilage repair)

After AMIC, many hip protocols use crutches and restricted weight-bearing for a period of time, then a staged progression back to full weight-bearing as pain and control allow. Range-of-motion work is usually started early but progressed carefully, with strengthening built up gradually.

Milestones often discussed in clinic include returning to desk-based work when sitting and walking are tolerable, and delaying driving until walking is steady and the hip can manage an emergency stop without hesitation. Higher-impact activity and sport are typically treated as a months-long target rather than a weeks-long one.

OCA (osteochondral allograft)

OCA is generally followed by a more cautious course because the hip joint surface is being reconstructed with a graft. Published femoral head OCA series via surgical hip dislocation report mid-term follow-up of roughly 3–4 years, and the rehabilitation approach in practice often reflects that “protect first, then build” principle: a period of limited weight-bearing, close review, then gradual strengthening before impact activity is considered.

Outcomes context (not rehab)

Across hip joint preservation techniques reported from 2018–2023, an updated systematic review found that most procedures improved patient-reported hip scores, but “survival” (avoiding revision arthroscopy or hip replacement) varied by technique. That same review includes single-study survival data for ChondroFiller gel in the hip literature.

OCA series also show that, despite meaningful improvements in hip scores, some hips still convert to arthroplasty within a few years—so even when rehabilitation goes well, cartilage repair is often framed as a way to delay further surgery rather than guarantee avoidance of hip replacement.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment in Grantham or Sleaford, with a consultant-led plan that sets out the expected rehabilitation checkpoints for the chosen procedure.

How do these options fit into long-term hip joint preservation?

Planning matters more than picking a single procedure, because hip joint preservation often succeeds or fails on whether the underlying mechanics are dealt with as well as the cartilage damage. In younger adults, that long-term plan may include a mix of image‑guided injection support (for symptoms and early joint care), focal cartilage restoration (for a defined defect), and—where shape is driving overload—corrective surgery to change how the hip is loaded. In a consultant-led pathway such as Lincolnshire Hip (Professor Paul Lee), this tends to be revisited over time, because what is realistic at 30 is not always the same at 40 or 50.

Where the hip’s shape is the main problem—classically acetabular dysplasia—cartilage procedures alone can be the wrong tool, because the cartilage is being worn by uneven contact. In appropriately selected patients, long-term follow-up studies in the hip preservation literature describe durable benefits after corrective surgery that improves joint mechanics.

Cartilage repair then sits alongside mechanical correction rather than competing with it. Expert hip cartilage reviews describe combining arthroscopic treatment of the underlying problem (such as femoroacetabular impingement and associated labral pathology) with cartilage treatment when a focal chondral defect is part of the same picture. In that combined frame, an ultrasound‑guided scaffold injection such as ChondroFiller may be considered when the goal is lower invasiveness and symptom support around a focal wear area, whereas AMIC is commonly discussed for symptomatic, full‑thickness defects where a membrane‑augmented marrow stimulation approach is preferred. For larger, deeper osteochondral injuries—especially in very young adults—osteochondral allograft remains the “big reconstruction” option, while accepting that published series still show a meaningful rate of later conversion to arthroplasty.

Microfracture alone increasingly sits at the back of the queue in modern hip cartilage discussions. A 2017 review framed microfracture mainly for smaller full‑thickness lesions, with membrane-based options such as AMIC reserved for larger defects and better results expected when arthritis is not established. More recently, a 2018–2023 updated systematic review reported joint “survival” ranges of 59.1%–100% for microfracture versus 92.9%–100% for AMIC in the available hip series, and included single-study survival data for ChondroFiller gel.

Comparative evidence also suggests lower conversion to total hip arthroplasty after AMIC than after microfracture alone in the available cohorts.

The most durable takeaway is a simple set of hinges that guide long-term decisions in the hip joint: mechanics first (dysplasia/impingement), then the type of cartilage problem (a focal “pothole” versus diffuse arthritis), and finally the time horizon (months of rehab versus years of preserved function). Even with newer scaffold-based techniques, hip evidence is still mostly mid-term rather than lifetime, so preservation is often about buying good years with the native hip—while keeping the option of hip replacement in reserve if the joint progresses.

1. [1] Arthroscopic treatment of chondral defects in the hip: AMIC, MACI, microfragmented adipose tissue transplantation (MATT) and other options. (2017). https://doi.org/10.1051/sicotj/2017029 https://doi.org/10.1051/sicotj/2017029